Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Medtronic
AstraZeneca
Dow
Boehringer Ingelheim

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,342,791


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,342,791 protect, and when does it expire?

Patent 10,342,791 protects ARAKODA and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 10,342,791
Title:Regimens of tafenoquine for prevention of malaria in malaria-naive subjects
Abstract: Methods of prevention of symptomatic malaria in a malaria-naive, G6PD-normal human subject comprising administering to the human subject a compound of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I). A compound of Formula (I) can be administered prior to potential exposure of a species of Plasmodium, during potential exposure of a species of Plasmodium, and after potential exposure of a species of Plasmodium. The methods of the invention also pertains to kits comprising specific doses of Formula (I), a pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising a compound of Formula (I), and instructions for administration of dosing quantity and frequency. The methods of the invention also pertain to determining doses of Formula (I) that meet the general regulatory requirement for a drug to be efficacious in the prevention of malaria in malaria-naive subjects. The methods of the invention further pertain to using the described algorithm to derive dosing regimens which can provide protection against symptomatic malaria in malaria-naive, G6PD-normal subjects. ##STR00001##
Inventor(s): Smith; Bryan L (Chevy Chase, MD), Jones; John P (Richmond, VA), Shmuklarsky; Moshe (Bethesda, MD), Balasubrahmanyam; Budda (Richmond, VA)
Assignee: 60 Degrees Pharmaceuticals LLC (Washington, DC) The United States Of America As Represented By The Secretary Of The Army (Washington, DC)
Application Number:15/532,280
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,342,791

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
60 Degrees Pharms ARAKODA tafenoquine succinate TABLET;ORAL 210607-001 Aug 8, 2018 RX Yes Yes ⤷  Try it Free ⤷  Try it Free FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,342,791

PCT Information
PCT FiledDecember 02, 2015PCT Application Number:PCT/US2015/063425
PCT Publication Date:June 09, 2016PCT Publication Number: WO2016/089995

International Family Members for US Patent 10,342,791

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015358566 ⤷  Try it Free
Australia 2020270452 ⤷  Try it Free
Canada 2968694 ⤷  Try it Free
China 107683278 ⤷  Try it Free
European Patent Office 3212621 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Boehringer Ingelheim
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.